ArticleNature communications2026
Sequence redesign of glycosyltransferases for enhanced heterologous expression and glycosylation efficiency in Escherichia coli.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Sequence redesign of glycosyltransferases for enhanced heterologous expression and glycosylation efficiency in Escherichia coli.Nature communications · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Heterologous expression of enzymes from higher organisms limits the construction of microbial cell factories for natural product biosynthesis. Here we develop a ProteinMPNN-based sequence redesign strategy, guided by essential structural features and evolutionary conservation, to improve the bacterial expression of heterologous enzymes. Applied to two plant glycosyltransferases, TOGT and UGT84A56, for esculetin glycosylation, this strategy generates extensively redesigned variants with markedly enhanced soluble expression and catalytic activity in Escherichia coli. In vitro enzyme assays and in vivo whole-cell conversions show consistent improvements, outperforming conventional solubility-enhancing strategies. Molecular simulations suggest that the improved performance arises from global optimization of hydrophobic and hydrophilic residue exposure while preserving productive substrate-binding interactions. Fed-batch fermentation achieved titers of 2.11 g/L cichoriin and 4.05 g/L aesculin. This work establishes a generalizable route for converting difficult-to-express eukaryotic enzymes into efficiently expressible and functional variants, thereby expanding the enzymatic toolbox for microbial cell factory construction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.